Artificial intelligence for precision therapeutics in age-related macular degeneration: current advances, challenges, and future directions
Frontiers in Artificial Intelligence · 17.08.2026 · 9
DOI: 10.3389/frai.2026.1822604 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Artificial Intelligence, online erschienen am 17.08.2026. Verfasst von Mini Han Wang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Shenzhen University of Advanced Technology, Shenzhen, China. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province.
Abstract (Originalsprache)
Age-related macular degeneration (AMD) is a leading cause of irreversible vision loss worldwide and is characterized by substantial clinical, imaging, and molecular heterogeneity that complicates disease prediction and therapeutic management. Recent advances in artificial intelligence (AI) and precision therapeutics have created new opportunities for more individualized and data-driven AMD care. AI models trained on multimodal datasets—including fundus photography, optical coherence tomography (OCT), optical coherence tomography angiography (OCTA), genetic susceptibility loci (e.g., CFH, ARMS2/HTRA1, C3, CFI, and APOE), and longitudinal clinical information—have demonstrated promising capability in early disease detection, progression forecasting, biomarker identification, and prediction of treatment response. These developments align closely with emerging precision therapeutic strategies, including optimized anti-vascular endothelial growth factor (anti-VEGF) regimens, complement-targeted therapies, gene-based interventions, and stem cell-associated regenerative approaches. This review provides a translational overview of AI-enabled precision therapeutics in AMD, with emphasis on multimodal biomarker integration, individualized therapeutic stratification, longitudinal disease monitoring, and clinically interpretable AI systems. Importantly, we further propose a Five-Level Clinical Readiness and Translational Utility Framework for AI in AMD Precision Therapeutics, categorizing AI applications according to evidence strength, clinical maturity, validation status, interpretability, and real-world implementation potential. The framework distinguishes near-reference-standard imaging AI systems, advanced clinical decision-support tools, emerging multimodal precision therapeutic AI, supportive workflow-oriented AI systems, and currently limited or unsuitable AI applications. Despite substantial progress, important translational barriers remain, including limited external validation, retrospective study designs, dataset heterogeneity, domain shift, insufficient explainability, regulatory uncertainty, and challenges related to workflow integration and real-world clinical deployment. Future advances in multimodal longitudinal AI, explainable AI, federated learning, digital health platforms, and multi-omics integration may facilitate a transition from reactive disease management toward more proactive, predictive, and personalized ophthalmic care. Collectively, AI-enabled precision therapeutics may help establish a more scalable and clinically integrated framework for individualized AMD management and future precision ophthalmology.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Shenzhen University of Advanced Technology, Shenzhen, China.
- Zhuhai People's Hospital (The Affiliated Hospital of Beijing Institute of Technology, Zhuhai Clinical Medical College of Jinan University), Zhuhai, Guangdong, China.
- Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, China.
- Zhuhai Institute of Advanced Technology, Chinese Academy of Sciences, Zhuhai, Guangdong, China.
- Department of Food Science and Nutrition, The Hong Kong Polytechnic University, Hong Kong, Hong Kong SAR, China.
- Faculty of Applied Sciences, Macao Polytechnic University, Macao, Macao SAR, China.
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Guangdong Province
Zitieren
APA
Wang, M. H., Lee, S. M. Y., Wang, Y., Alves, J. C., Xie, R., He, Y., Hou, G., Fang, X., Yu, Y., Cai, X., Zheng, S., Liu, J., Cheang, C., Kuok, K. I., & Qin, S. (2026). Artificial intelligence for precision therapeutics in age-related macular degeneration: current advances, challenges, and future directions. Frontiers in Artificial Intelligence, 9. https://doi.org/10.3389/frai.2026.1822604
Vancouver
Wang MH, Lee SMY, Wang Y, Alves JC, Xie R, He Y, et al. Artificial intelligence for precision therapeutics in age-related macular degeneration: current advances, challenges, and future directions. Frontiers in Artificial Intelligence. 2026;9. doi:10.3389/frai.2026.1822604
BibTeX
@article{Wang2026,
author = {Wang, Mini Han and Lee, Simon Ming Yuen and Wang, Yapeng and Alves, José C and Xie, Ruitao and He, Yaqing and Hou, Guanghui and Fang, Xiaoxiao and Yu, Yang and Cai, Xiaodong and Zheng, Shuai and Liu, Jin and Cheang, Chonin and Kuok, Kai Ian and Qin, Shuai},
title = {Artificial intelligence for precision therapeutics in age-related macular degeneration: current advances, challenges, and future directions},
journal = {Frontiers in Artificial Intelligence},
year = {2026},
volume = {9},
doi = {10.3389/frai.2026.1822604}
}
EUVIMED